Latest Patents News

Impact Minerals reports a robust Preliminary Feasibility Study for its Lake Hope High Purity Alumina project, underpinned by strong economics and low production costs, while strategically acquiring a 50% stake in Alluminous Pty Ltd to fast-track market entry with HiPurA® technology.

Ionic Rare Earths’ Belfast plant is ramping up production of critical heavy rare earth oxides to meet soaring demand from Western markets following China’s export restrictions. This strategic move positions the company as a key supplier for defence, renewables, and advanced manufacturing sectors.

BrainChip Holdings reported a solid June quarter with $13.5 million in cash, increased customer inflows, and a strategic decision to remain listed on the ASX. The company advanced multiple commercial collaborations and expanded its intellectual property portfolio, signaling confidence in its edge AI technology roadmap.

Nanoveu Limited has accelerated its commercial and technological momentum with a $3.02 million capital raise, a breakthrough 33% increase in drone flight time using its edge-AI chip, and progress toward a U.S. OTCQB listing.

Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.

EcoGraf Limited has advanced its vertically integrated battery anode materials business with a US$105 million financing mandate for its Epanko Graphite Mine and positive momentum in US and EU government support.

ASF Group Limited reported a stable cash position of $1.3 million as of June 2025, accepted a takeover offer for its stake in Rey Resources, and continued to develop its innovative technology and biotech investments.

Atomo Diagnostics reports strong commercial momentum in Q4 FY25, highlighted by a major US supply agreement, rapid growth in HIV self-test sales, and promising data for its syphilis test.

Firetail Resources has revealed a significant expansion of gold discovery potential at its Excelsior Gold Project in Nevada, identifying a 5km strike extension of the Buster Trend and confirming a parallel Ghost Trend. The company is poised to begin diamond drilling in August to test these promising targets.

Paradigm Biopharmaceuticals has advanced its global Phase 3 trial for knee osteoarthritis pain with active patient recruitment in Australia and the US, backed by a $41.2 million convertible note facility. The company also expanded its osteoarthritis portfolio through the acquisition of Proteobioactives and the Pentacoxib™ oral therapy.

Anatara Lifesciences reports Phase II GaRP-IBS trial results showing no safety concerns but missing the primary efficacy endpoint, while securing key patents and receiving a significant R&D tax refund.

Algorae Pharmaceuticals has advanced its AI-driven drug discovery platform into preclinical validation through a strategic collaboration with the Peter MacCallum Cancer Centre, while progressing its therapeutic pipeline and commercial leadership.